Good MorningEquity markets reversed two days of losses to advance to a new high on Wednesday following better-than-expected economic data. Investors cheered hot ISM services and Factory Orders data suggesting both aspects of the US economy are regaining momentum. If true, investors should also expect another uptick in inflation as demand puts added pressure on the economy.
In other news, oil prices continue to slide and fall below key support at the $96 level following a slight increase in production from OPEC. This move may trigger additional selling, but the worse news is the implication for the economy. Oil prices are not expected to contract without a major slow down in activity, and we've yet to see one. In this light, the decline in oil prices is either a precursor to a deeper economic recession or a whipsaw move and buying opportunity. Featured: Sell these "safe" blue chips immediately (Ad) 
|
Energy | |
The entire energy infrastructure complex is moving higher and Energy Transfer LP (NYSE: ET) may lead the bunch. The company’s diversified approach to energy and its reliance on fee-based income make it stand out from other energy companies and its own peers. Trading at 7.33X its earnings it ... Read the Full Story |
|
From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
|
Energy | |
Devon Energy (NYSE:DVN) may be an overlooked company in the oil and gas sector. However, that may change after the company releases earnings this week. The $5.63 billion in revenue beat expectations by 18%. And on the bottom line, the news was equally impressive, with the company posting $2.59 ear... Read the Full Story |
|
Finance | |
Typically when a mature company’s share price is hovering around $20 or below, it means that growth prospects are limited. But that’s not always the case.
As we’ve seen during this year’s market downturn, even well-run, fundamentally sound companies can get dragged down wi... Read the Full Story |
|
From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
|
Healthcare | |
The health care sector is just barely participating in the S&P 500’s nascent rally, but pharmaceuticals such as AbbVie (NYSE:ABBV), Merck (NYSE:MRK) and Pfizer (NYSE:PFE) are holding up well relative to the broader market.
All three reported earnings recently, and while none got a boun... Read the Full Story |
|
Communication Services | |
Media entertainment company Warner Brothers Discovery (NYSE: WBD) stock has languished since its spin-off as it fell to new all-time lows at $12.77 and down (-41%) year-to-date. Formerly Discovery Networks, the merging with WarnerMedia has created a content powerhouse including popular brands like... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Consumer Discretionary | |
Institutional Support For Under Armour (NYSE: UA) is on the rise, albeit still low at only 37%. The salient point is that, after 3 consecutive quarters of net-selling, the institutional activity shifted in Q2 2022 and bullishness is carrying into the 3rd quarter as well. The institutional activity... Read the Full Story |
|
Technology | |
Enterprise software makers like Palantir Technologies (NYSE: PLTR) and Shopify (NYSE: SHOP) are continuing to languish in correction mode, even as the broader market attempts to stage a rally.
In Wednesday’s trading, major U.S. indexes notched strong gains, with the tech-heavy Nasdaq leadi... Read the Full Story |
|
Healthcare | | Amarin (NASDAQ: AMRN), a penny stock that has caught the attention of speculators and serious investors alike has recently reported its Q2'22 earnings card that came with mixed results. The company's EPS finished on -$0.09, missing its consensus EPS target of $0.03. Some positive news for the compan... Read the Full Story |
|
Communication Services | |
Roku (NASDAQ: ROKU) is set to announce its earnings this Thursday. One outcome for the company is that it may surprise investors with a better-than-expected performance for its reporting quarter. This would not be unusual, as the company's chief rival Netflix (NASDAQ: NFLX) also beat expectations.... Read the Full Story |
|
Consumer Staples | |
Molson Coors Beverage (NYSE: TAP) is down over 7% after the company delivered a mixed earnings report on August 2. Profits for the adult beverage company came in right on the number at $1.19 per share. However, revenue was a slight miss at $2.92 billion with the forecast calling for $2.94 billion.... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada. | | View Today's Stock Pick |
|
